# DESCRIPTION

## FIELD OF THE INVENTION

- relate to isolated antibodies

## BACKGROUND OF THE INVENTION

- introduce PDGFs
- describe PDGF signaling
- explain PDGF-C and PDGF-D chains
- describe PDGF-CC activation
- discuss PDGF-CC role in angiogenesis
- discuss inhibition of PDGF-CC activity
- describe PDGF-CC as therapeutic target
- discuss PDGF-CC role in blood-brain barrier integrity

## SUMMARY OF THE INVENTION

- introduce anti-PDGF-C antibodies
- describe epitope of PDGF-C
- define anti-PDGF-C antibodies
- list monoclonal antibodies (mAbs)
- describe light and heavy chain CDRs of 6B3
- describe light and heavy chain CDRs of ch6B3
- describe light and heavy chain CDRs of 11F5
- describe light and heavy chain CDRs of 12F5
- describe light and heavy chain CDRs of 19C7
- describe light and heavy chain CDRs of hu6B3
- describe nucleic acid sequences of anti-PDGF-C antibodies
- describe expression vector and host cell
- describe treatment methods using anti-PDGF-C antibodies
- modulate PDGF-CC activity in a cell
- inhibit PDGF-CC autocrine or paracrine signaling
- reduce angiogenesis, stromal support, cell viability, tumor size
- modulate PDGF-CC activity in the blood-brain barrier
- inhibit PDGF-CC mediated opening of the blood-brain barrier
- reduce opening of the blood-brain barrier by CNS pathologies
- describe diagnostic assays and drug screen assays
- use anti-PDGF-C antibodies as a molecular tool
- describe kit for detecting PDGF-C peptide
- modulate permeability of blood-brain barrier
- treat cerebrovascular disease or condition
- describe non-human transgenic animal
- define heterologous PDGF-C gene
- describe humanized mouse PDGF-C protein
- define homology
- describe percent identity between sequences
- describe algorithm for determining percent identity
- define substantially homologous
- define heterologous polypeptide, nucleic acid, or gene
- define transgene
- define transgenic cell and animal
- define epitope
- describe isolated antibodies/specific binding members
- describe subject or patient
- define treating or treatment of a disease

## DETAILED DESCRIPTION OF THE INVENTION

- introduce PDGF-C as a molecular hallmark for carcinomas
- link PDGF-C to angiogenesis and tumor growth
- describe PDGF-C expression in disease states
- present anti-PDGF-C antibodies as a viable target
- define isolated antibodies that interact with PDGF-C
- describe modulation of PDGF-CC activity
- outline treatment of disease or condition associated with PDGF-C expression
- provide amino acid sequence of human form of PDGF-C protein
- include variants of PDGF-C that exhibit properties
- define targeted epitope(s) of anti-PDGF-C antibodies
- describe binding of antibodies to PDGF-C
- outline reduction of PDGF-CC activity
- provide epitope within PDGF-CC core active domain
- describe anti-PDGF-C antibodies with two heavy chains and two light chains
- outline variable and constant domains of light and heavy chains
- describe isotypes of antibodies, including IgA, IgD, IgE, IgG, and IgM
- outline effector functions of antibodies, including CDC and ADCC
- describe isotypes with significant effector function
- outline isotypes with reduced effector functions
- describe Fc region of antibody and its association with Fc receptor binding
- outline Fv region of antibody and its antigen-binding site
- describe framework regions and complementarity-determining regions
- provide amino acid sequences of variable light and heavy chains
- describe isolated nucleic acid molecules encoding amino acid sequences
- outline variants of antibody sequences with improved affinity
- define conservative modifications
- describe amino acid substitutions
- list families of amino acid residues
- describe modifications of antibody
- describe linking to polymers
- describe entrapping in microcapsules
- describe nucleic acids substantially free from other nucleic acids
- describe subcloning into expression vector
- describe transfecting into host cell
- describe generating alternative antibody forms
- describe codon redundancy
- describe RNA editing
- describe mutations improving physical properties
- describe affinity matured versions of antibody
- describe mutated forms of antibody
- describe recombinant vectors and hosts
- describe nucleic acid molecules encoding heavy and/or light regions
- describe linking with other DNA molecules
- describe forming recombinant DNA molecules
- describe methods of subcloning and transfecting
- describe harvesting antibody from host cells
- describe expression vectors
- describe promoters and transcription regulatory elements
- describe transferring expression construct into host cell
- describe producing recombinant protein
- describe expression vectors for eukaryotic DNA
- describe techniques for manipulating DNA
- describe commercially available expression vectors
- describe bacterial, fungal, and insect cell expression vectors
- describe recombinant host cells
- describe mammalian cell lines
- describe adapting or engineering antibodies
- describe single variable domains and antigen binding proteins
- describe chimeric antibodies
- describe humanized antibodies
- describe grafting CDRs onto human variable domains
- describe modifying variable domains to reduce immunogenicity
- describe mutating CDRs and/or FR regions
- describe uses of anti-PDGF-C antibodies

### Treatment Methods and Pharmaceutical Formulations

- introduce anti-PDGF-C antibodies
- describe administration methods
- motivate PDGF-CC inhibition
- list PDGF-C expressing cell types
- describe treatment of cancer cell types
- describe treatment of PDGF-CC-associated diseases
- motivate BBB modulation
- describe treatment of CNS diseases
- describe treatment of cerebral edema
- describe administration modes
- describe intrathecal administration
- describe intranasal administration
- describe lumbar region administration
- describe cisterna magna administration
- describe cerebral ventricle administration
- describe infusion pumps
- describe combination therapy
- describe tPA combination therapy
- define treatment
- describe prophylactic measures
- describe therapeutic measures
- describe administration with chemotherapeutic agents
- describe pharmaceutical composition formulation
- describe solution formulation
- describe parenteral solution formulation
- describe diluents
- describe carriers
- describe excipients
- describe bacteriostats
- describe cryoprotectants
- describe salts
- describe divalent cations
- describe non-ionic surfactants
- describe Pluronic series surfactants
- describe other carriers and excipients
- describe ionic binding
- describe gel encapsulation
- describe physical trapping
- describe iontophoresis
- describe soaking
- describe dosage regimen factors
- describe effective dosage range
- describe depot injection or implant preparation

### PDGF-C/PDGF-CC Detection/Diagnosis Assays

- introduce immunoassays for PDGF-C and PDGF-CC detection
- describe two-site sandwich assay
- describe single site immunoassay
- explain forward sandwich assay
- explain simultaneous assay
- explain reverse sandwich assay
- describe binding processes
- describe reporter molecules
- explain enzyme immunoassay
- explain fluorescent compounds
- describe immunofluorescence and EIA techniques
- mention other reporter molecules
- describe single site immunoassay procedure
- explain use of general antibody
- summarize immunoassay techniques

### Kits

- introduce kits and diagnostic systems
- describe kit components
- explain target-specific antibody
- describe reagents for detecting binding
- mention control reagent and instructions
- describe diagnostic kit components
- explain secondary antibody
- describe kit container and packaging
- mention instructions and software
- summarize kit components and uses

### Drug Screening Assay

- introduce drug screening assay
- describe antibody/peptide/test compound interaction assays
- explain compound selection and identification
- mention various antibody/antigen-based assays

## EXAMPLES

### Example 1—Generation of Monoclonal Antibodies to Human PDGF-CC

- generate monoclonal antibodies to human PDGF-CC
- produce and purify PDGF-CC core domain fragment
- immunize mice with PDGF-CC core domain fragment
- generate hybridomas and assess for PDGF-CC binding specificity
- select antibodies with expected reactivity pattern
- analyze binding of hybridoma supernatants to PDGF-CC
- determine isotype and CDRs of selected antibodies
- analyze binding of purified antibodies to PDGF-CC

### Example 2—Amino Acid Sequence of Antibodies

- determine amino acid sequence of variable heavy and light chains

### Example 3—Generation of Chimeric Anti-PDGF-CC Antibody 6B3 (ch6B3)

- generate chimeric antibody 6B3
- express and purify ch6B3 antibody

### Example 4—Identification of the 6B3 Binding Epitope on PDGF-C

- predict 6B3 binding epitopes on PDGF-CC core antigen
- synthesize putative peptides for biosensor analyses
- analyze binding of 6B3 to immobilized PDGF-CC core antigen
- determine effect of peptides on 6B3 binding to PDGF-CC
- identify peptide 3 as specific inhibitor of 6B3 binding
- analyze binding of 6B3 to immobilized peptide 3
- synthesize overlapping peptides to refine 6B3 epitope
- analyze binding of 6B3 to overlapping peptides
- determine specific PDGFC peptide sequence bound by 6B3
- analyze binding of 6B3 to PDGF-C and PDGF-D peptides

### Example 5—Biosensor Confirmation of Human PDGF-CC Specificity

- estimate apparent affinity of anti-PDGF-CC mAbs
- analyze binding of anti-PDGF-CC mAbs to PDGF-CC and PDGF-DD
- determine apparent on-rate, off-rate, and dissociation constants
- analyze competitive binding of anti-PDGF-CC mAbs
- map epitopes of anti-PDGF-CC mAbs
- analyze binding of anti-PDGF-CC mAbs to reduced and alkylated PDGF-CC
- determine effectiveness of mAbs to cross-compete for binding
- diagram epitope groups for anti-PDGF-CC mAbs

### Example 6—PDGF-Ligand Induced Receptor Activation and Cell Proliferation

- stimulate PAE cells with PDGF-CC and analyze PDGFR-α activation
- analyze effect of anti-PDGF-CC mAbs on PDGF-CC-induced PDGFR-α activation
- determine neutralizing activity of anti-PDGF-CC mAbs
- analyze effect of 6B3 on PDGF-CC-induced PAE cell proliferation
- determine dosage-dependent inhibition of PAE cell proliferation by 6B3

### Example 7—Immunohistochemistry—Tissue Screens

- introduce immunohistochemical analysis
- describe materials and methods
- detail human tissue sources
- outline paraffin-embedded section preparation
- describe antigen retrieval
- detail antibody binding detection
- outline assay controls
- define test tissue reporting
- describe competition with PDGF-CC ligand
- detail slide digitization
- outline 6B3 staining reporting
- describe CD34 antibody application
- detail 6B3 staining parameters
- calculate modified H-score
- conduct t-tests for statistical significance
- present results of normal tissue staining
- describe normal tissue staining patterns
- present results of tumor tissue staining
- describe tumor tissue staining patterns
- compare normal and tumor tissue staining
- analyze modified H-scores for statistical significance
- discuss results and implications
- conclude on PDGF-CC expression in normal and tumor tissues

### Example 8—In Vivo Therapy Studies

- introduce in vivo therapy studies
- describe colon carcinoma xenografts
- detail cell line selection
- outline in vivo investigation methods
- describe tumor xenograft establishment
- detail treatment with 12F5, 6B3, or PBS
- outline tumor volume measurement
- describe animal sacrifice and tumor removal
- detail pharmacodynamic assessments
- present results of colon carcinoma xenografts
- describe Colo205 xenograft pharmacodynamic assessments
- detail tissue preparation and histology
- outline immunostaining methods
- present results of vessel assessments
- present results of cell proliferation assessments
- describe MDA-MB-231 breast carcinoma xenografts
- present results of orthotopic tumor model

### Example 9—Modulation of PDGF-CC Mediated Opening of the Blood-Brain Barrier by Anti-PDGF-C Antibody 6B3

- introduce experimental design
- describe antibody injection procedure
- describe PDGF-CC injection procedure
- describe Evans Blue injection procedure
- describe brain dissection and photography
- describe Evans Blue quantification
- present results of Evans Blue extravasation
- discuss significance of results
- describe antibody administration timing
- describe antibody administration route
- discuss effect of antibody on blood-brain barrier opening
- discuss effect of antibody on Evans Blue extravasation
- present quantification of Evans Blue extravasation
- discuss significance of results
- describe experimental design
- describe animal model
- describe antibody treatment
- describe stroke model
- describe assessment of stroke volume
- describe assessment of hemorrhage score
- present results of stroke volume
- present results of hemorrhage score
- discuss significance of results
- describe prophylactic treatment
- describe therapeutic treatment
- present results of prophylactic treatment
- present results of therapeutic treatment
- discuss significance of results
- introduce humanized antibody generation
- describe humanization process
- present results of humanized antibody binding

